NASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for the treatment of NASH. Starting with fat accumulation in liver, this condition can progress to cirrhosis and liver failure. NASH ranks as one of the major causes of cirrhosis, behind hepatitis C and alcoholic liver disease. Liver transplantation is the only option for managing advanced cirrhosis with liver failure.
Saroglitazar Magnesium was launched in India during September 2013, for the treatment of hypertriglyceridemia and diabetic dyslipidemia in patients with type-2 diabetes not controlled by statins. Saroglitazar Mg has demonstrated beneficial effects in NASH animal models. Saroglitazar Mg favorably affects all components of NASH including steatosis, ballooning, inflammation and fibrosis in NASH models. Saroglitazar Mg has previously demonstrated improvement in both liver enzymes along with favorable effects on lipid and glycemic indices in patients with nonalcoholic fatty liver disease in Phase II clinical trials.
Zydus had also achieved positive results in EVIDENCES II Phase 3 biopsy-driven trial of Saroglitazar 4 mg versus Placebo in patients with Non-Alcoholic SteatoHepatitis. The primary endpoint evaluated the histological improvement of NASH using liver biopsy at the end of 52 weeks. Separately, the results of EVIDENCES IV trial of Saroglitazar Mg in patients with NASH were presented as a Late Breaker at The Liver Meeting 2019, the annual meeting of the American Association for the Study of Liver Diseases.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content